NALP3 Activation Triggers Development of AMD
Principal Investigator
Bruce Ksander, PhD
Schepens Eye Research Institute of Massachusetts Eye and Ear
Boston, MA, USA
About the Research Project
Program
Award Type
Standard
Award Amount
$99,836
Active Dates
July 01, 2011 - June 30, 2013
Grant ID
M2011069
Goals
Age related Macular Degeneration (AMD) causes loss of vision and blindness in elderly patients when two types of cells are damaged (i) RPE (called retinal pigment epithelial cells), and (ii) photoreceptors. We discovered a gene (called NALP3) is expressed in retinal cells during the development of AMD. We predict this gene is important in triggering this disease via the activation of localized inflammation.
Summary
Retinal pigment epithelial (RPE) cells support the light‐detecting photoreceptor cells by recycling and removing waste products. If RPE cells are unhealthy, then this waste can build up and damage the retina. Inflammation is an important part of the AMD disease process, and RPE cells have their own special type of proteins—called the “inflammasome”—to monitor and determine if the RPE is working properly. In fact, if this RPE waste recycling and removal process isn’t functioning properly, the inflammasome sends out signals for the immune system to swoop in and kill the malfunctioning RPE cells. Dr. Ksander and collaborators have discovered a new risk gene—called NALP3— that is expressed in retinal cells and is suspected to be important in triggering AMD via the inflammasome. These researchers will determine whether this gene is involved in the death of RPE cells and, if so, whether it will be a new target for the treatment of AMD.
Related Grants
Macular Degeneration Research
How Aging of the Immune System Affects Age-Related Macular Degeneration
Active Dates
July 01, 2025 - June 30, 2028
Principal Investigator
Masayuki Hata, MD, PhD
Current Organization
Kyoto University
How Aging of the Immune System Affects Age-Related Macular Degeneration
Active Dates
July 01, 2025 - June 30, 2028
Principal Investigator
Masayuki Hata, MD, PhD
Current Organization
Kyoto University
Macular Degeneration Research
Microglia’s Roles in AMD to Inform Therapies for Vision Loss Prevention
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Nobuhiko Shiraki, PhD
Current Organization
Duke University School of Medicine
Microglia’s Roles in AMD to Inform Therapies for Vision Loss Prevention
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Nobuhiko Shiraki, PhD
Current Organization
Duke University School of Medicine
Macular Degeneration Research
The Novel Role of an Intracellular Nuclear Receptor in AMD Pathogenesis
Active Dates
July 01, 2024 - June 30, 2026
Principal Investigator
Neetu Kushwah, PhD
Current Organization
Boston Children’s Hospital
The Novel Role of an Intracellular Nuclear Receptor in AMD Pathogenesis
Active Dates
July 01, 2024 - June 30, 2026
Principal Investigator
Neetu Kushwah, PhD
Current Organization
Boston Children’s Hospital